ImmunityBio (IBRX) Shares Outstanding (Weighted Average) (2013 - 2026)

ImmunityBio (IBRX) has 14 years of Shares Outstanding (Weighted Average) data on file, last reported at $1.0 billion in Q1 2026.

• Shares Outstanding (Weighted Average) for Q1 2026 came in at $1.0 billion, up 20.36% year-over-year; the trailing twelve-month figure through Mar 2026 was $1.0 billion (up 20.36% YoY), and the FY2025 annual result was $919.9 million, up 31.92% from the prior year.
• Shares Outstanding (Weighted Average) advanced to $1.0 billion in Q1 2026 per IBRX's latest filing, from $65.1 million in the prior quarter.
• Over five years, Shares Outstanding (Weighted Average) peaked at $1.0 billion in Q1 2026 and troughed at $1.6 million in Q1 2022.
• A 5-year average of $490.2 million and a median of $508.6 million in 2023 frame the typical range for Shares Outstanding (Weighted Average).
• The sharpest annual moves came in 2022 and 2024: Shares Outstanding (Weighted Average) slumped 99.57% in 2022, then surged 40976.37% in 2024.
• A 5-year view of Shares Outstanding (Weighted Average) shows it stood at $9.1 million in 2022, then soared by 5495.0% to $508.6 million in 2023, then jumped by 37.09% to $697.3 million in 2024, then slumped by 90.67% to $65.1 million in 2025, then soared by 1478.51% to $1.0 billion in 2026.
• Business Quant data shows IBRX's Shares Outstanding (Weighted Average) at $1.0 billion in Q1 2026, $65.1 million in Q4 2025, and $946.6 million in Q3 2025.